Fig. 4: Waterfall plots of tebentafusp therapy.
From: Identifying biomarkers for treatment of uveal melanoma by T cell engager using a QSP model
Varying a tumor growth rate; b half-maximal PD1-PDL1 for Teff inhibition; c Kd of antigen; d rate of Teff death by Treg; e rate of T cell exhaustion by cancer cell; f Neo-Ag specific T cell clone.
